Form 4: Crinetics Pharmaceuticals CFO Marc Wilson Reports Stock Transactions
SEC Form 4
CFO Marc Wilson reports the disposition and sale of Crinetics Pharmaceuticals (CRNX) common stock related to tax obligations and a pre-arranged trading plan.
Summary
- Marc Wilson, CFO of Crinetics Pharmaceuticals, reported transactions involving the company's common stock.
- On March 18, 2024, 3,983 shares were disposed of to cover tax withholding obligations at a price of $38.14 per share.
- On March 19, 2024, 6,942 shares were sold at a weighted average price of $42.91 per share, with prices ranging from $41.04 to $44.00.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
- Following these transactions, Wilson directly owns 110,630 shares of Crinetics Pharmaceuticals.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings provide transparency to the market regarding insider transactions.
Stakeholder Impact
- Shareholders are informed about insider trading activity, which can influence investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/28/2022 | Date of Restricted Stock Units grant related to tax withholding obligation. |
| 03/01/2023 | Date of Restricted Stock Units grant related to tax withholding obligation. |
| 03/18/2024 | Disposition of 3,983 shares for tax withholding. |
| 03/19/2024 | Sale of 6,942 shares under Rule 10b5-1 trading plan. |
| 03/20/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.